CIA
GILD icon

Capital Impact Advisors’s Gilead Sciences GILD Stock Holding History

Capital Impact Advisors’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-15,024
Closed -$1.06M – 147
2017
Q2 		$1.06M Hold
15,024
– – 0.48% 112
2017
Q1 		$1.02M Sell
15,024
-1,474
-9% -$104K 0.41% 131
2016
Q4 		$1.18M Hold
16,498
– – 0.49% 67
2016
Q3 		$1.3M Hold
16,498
– – 0.56% 48
2016
Q2 		$1.38M Sell
16,498
-757
-4% -$67.2K 0.64% 26
2016
Q1 		$1.58M Sell
17,255
-5,232
-23% -$472K 0.76% 17
2015
Q4 		$2.28M Hold
22,487
– – 1.09% 3
2015
Q3 		$2.21M Hold
22,487
– – 1.12% 9
2015
Q2 		$2.63M Buy
22,487
+6,000
+36% +$656K 1.19% 3
2015
Q1 		$1.62M Buy
+16,487
New +$1.67M 0.74% 25

Other funds holding GILD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Parnassus Investments
Parnassus Investments San Francisco, California $34.1B AUM 20.22% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Capital Impact Advisors's GILD Position: Q3 2017 in Review

Capital Impact Advisors sold out of Gilead Sciences (GILD) in Q3 2017, closing a stake of 15,024 shares — an estimated $1.06M sold.

Capital Impact Advisors first reported a position in GILD in Q1 2015 and held it in 10 quarters. The position peaked at $2.63M in Q2 2015. 1,503 funds tracked by Wall St. Rank hold GILD as of Q3 2017.

  • Capital Impact Advisors reported no remaining Gilead Sciences position as of Q3 2017 after selling out during the quarter.
  • Capital Impact Advisors sold 15,024 Gilead Sciences shares in Q3 2017, an estimated $1.06M.
  • Capital Impact Advisors first reported a position in Gilead Sciences in Q1 2015 and held it in 10 quarters.
  • Capital Impact Advisors's Gilead Sciences position peaked at $2.63M in Q2 2015.
  • 1,503 funds tracked by Wall St. Rank held Gilead Sciences as of Q3 2017.

Based on Capital Impact Advisors's 13F filing for Q3 2017, filed 16 Jan 2018.